Which Bisphosphonate? It's the Compliance!: Decision Analysis
Journal of Bone Metabolism
;
: 79-83, 2016.
Article
in English
| WPRIM
| ID: wpr-213428
ABSTRACT
BACKGROUND:
The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life.METHODS:
A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty.RESULTS:
The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589.CONCLUSIONS:
In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quality of Life
/
Decision Trees
/
Decision Support Techniques
/
Patient Compliance
/
Compliance
/
Uncertainty
/
Consensus
/
Diphosphonates
/
Osteoporotic Fractures
/
Hip
Type of study:
Practice guideline
/
Health economic evaluation
/
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Journal of Bone Metabolism
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS